The Current State of HIV in Nigeria: An Overview

Nigeria carries the second-largest HIV burden of any country in the world, with roughly two million adults living with the virus and a national prevalence among adults aged 15 to 49 that Bayesian modeling places at about 2.1%.¹ Behind that single-digit national figure lies enormous variation by geography, population group, age, and gender, and the country’s response has made real gains in treatment while still struggling with prevention gaps, stigma, and a fragile supply chain.

Geographic Variation Across States

National averages obscure a stark north-south divide. States in Nigeria’s southern and eastern regions consistently report the highest HIV prevalence. Bayesian estimates put Benue at roughly 5.7% and Rivers at about 5.2%, while Akwa Ibom hovers around 3.5 to 4.3% depending on the model and reference year.¹ By contrast, many states across the north and northwest have prevalence below 1%, with Jigawa sitting at roughly 0.3% and Zamfara at about 0.3% as well.²

The variation does not stop at the state level. Within high-prevalence states, certain local government areas register rates above 8%, while neighboring areas may sit closer to 2%.² That degree of patchiness makes blanket national strategies insufficient. Resources directed at a 1.4% national prevalence miss the communities where one in twelve adults is living with HIV, and over-allocate to regions where the epidemic barely registers.

Key Populations and Concentrated Epidemics

Nigeria’s general-population prevalence may look modest next to southern and eastern African countries, but the epidemic is deeply concentrated among groups that public-health frameworks call key populations: men who have sex with men, female sex workers, people who inject drugs, and transgender individuals. The most recent national integrated biological and behavioural surveillance survey, conducted in 2020–2021, found weighted HIV prevalence of about 29% among transgender individuals, 25% among men who have sex with men, roughly 16% among female sex workers, and 11% among people who inject drugs.³ Those figures dwarf the general population rate by a factor of ten or more.

Among men who have sex with men specifically, prevalence has been climbing over time, from about 14% in 2007 to 23% by 2014, with older age, receptive anal sex, and a history of sexually transmitted infections identified as key risk factors.⁴ Condom use remains low across all key population groups, particularly with regular (as opposed to casual) partners. A large proportion of men who have sex with men and transgender individuals reported unprotected receptive anal intercourse, with rates between 71% and 85%.³ Among people who inject drugs, close to 60% reported sharing used syringes.³ Psychoactive substance use compounds risk: roughly a quarter of female sex workers and men who have sex with men surveyed had ever used psychoactive drugs, and among those, a substantial share had injected drugs recently.⁵

Treatment Gains and Viral Suppression

The treatment side of Nigeria’s HIV response has improved dramatically. Among people on antiretroviral therapy, viral suppression rates (using the standard threshold of fewer than 1,000 copies per milliliter) climbed from about 72% in 2016 to nearly 96% in 2022.⁶ Even at the more stringent threshold of fewer than 50 copies per milliliter, the rate jumped from about 47% to 87% over the same period.⁶ That is a meaningful jump, and it means that the majority of Nigerians who are on treatment and getting their viral load tested are achieving suppression.

The catch is that “on treatment and getting tested” leaves out a lot of people. Not everyone living with HIV has been diagnosed, not everyone diagnosed has started therapy, and not everyone on therapy stays on it. Differentiated service delivery models have been rolled out to try to bridge retention gaps. In one large-scale program across Akwa Ibom and Cross River states, retention rates at six months exceeded 96% regardless of which community or facility model was used, compared with 94% in standard care.⁷ Qualitative feedback from people living with HIV suggests that these models, which may include multi-month medication dispensing and community-based refills, improve adherence, lower costs, and reduce the burden of frequent clinic visits.⁸ Mobile phone-based reminder systems have also shown promise for improving clinic attendance.⁹

Drug Resistance on the Rise

As more people take antiretroviral therapy and as some cycle on and off treatment, drug-resistant strains of HIV gain a foothold. A population-based survey of Nigerian adults with detectable viral load found that roughly one in five had resistance mutations to at least one class of antiretroviral drug, with the most common resistance directed against the older drug classes: non-nucleoside reverse transcriptase inhibitors (about 18%) and nucleoside reverse transcriptase inhibitors (about 11%).¹⁰ Among people recently infected, transmitted resistance was found in about 14% of cases.¹⁰

For key populations the picture can be sharper still. Among treatment-experienced men who have sex with men and transgender women in one study, resistance to the older non-nucleoside drugs was found in about 43% of those tested, and nucleoside resistance in about 24%.¹¹ Encouragingly, resistance to dolutegravir, the integrase inhibitor now at the center of Nigeria’s first-line treatment, has so far been rare.¹² Keeping it that way depends on stable drug supply and strong adherence support, because the virus adapts quickly when treatment is interrupted or taken inconsistently.

Tuberculosis and Hepatitis Co-infections

Tuberculosis is the leading killer of people living with HIV globally, and Nigeria is no exception. Hospital-based studies across the country have consistently found that roughly 20 to 37% of TB patients are co-infected with HIV.¹³¹⁴ Treatment outcomes for co-infected patients remain poor compared to those with TB alone: in one southeastern Nigerian cohort, only about 41% of co-infected patients achieved treatment success, while roughly 11% died during treatment and nearly half defaulted or were transferred out.¹⁵ Having both TB and HIV was associated with roughly 2.7-fold higher odds of a poor treatment outcome compared with TB alone.¹³

Viral hepatitis adds another layer. Among people attending HIV care at a large southeastern Nigerian facility, about 8% tested positive for hepatitis B surface antigen and roughly 5% for hepatitis C antibodies.¹⁶ Co-infection with hepatitis B is a major consideration in drug selection, because some antiretrovirals (particularly tenofovir) have activity against both viruses, while stopping them abruptly can trigger dangerous hepatitis B flares. Hepatitis C co-infection, while somewhat less common in Nigeria than in settings with widespread injection drug use, still warrants screening, especially given the availability of highly effective direct-acting antiviral cures.¹⁷

Women, Girls, and Prevention of Mother-to-Child Transmission

Young women and adolescent girls face a set of intersecting vulnerabilities that elevate their HIV risk. Poverty, limited education, and economic dependence on men push some into transactional sex or relationships with older partners in which they lack the power to negotiate condom use.¹⁸ These structural drivers are especially pronounced in lower-wealth households, where risky sexual behavior among adolescent girls and young women persists as a leading pathway to new infections.¹⁹

For women already living with HIV who become pregnant, prevention of mother-to-child transmission programs have made strides. At one tertiary center that tracked over 1,500 infants born to HIV-positive mothers over six years, early infant diagnosis found only about 0.9% of those infants to be HIV-positive, a rate well below what would be expected without intervention.²⁰ That is an encouraging number, but it comes from a well-resourced tertiary hospital. In rural primary-care settings where many Nigerian women deliver, access to antenatal HIV testing and timely antiretroviral prophylaxis can be spotty.

Children and Adolescents on Treatment

Pediatric HIV care in Nigeria has made progress, but children face steeper challenges than adults at nearly every step. In a seven-year retrospective study of 660 children enrolled in HIV care, about 64% were still retained on treatment at the end of the period, 16% had been lost to follow-up, and 10% had died.²¹ Disease stage, CD4 count, age, and the year treatment was started all predicted mortality. A separate multi-site analysis found that loss to follow-up was highest among children aged roughly two to six years, with about 36% of that group lost, and that overall documented mortality within 90 days of starting treatment was about 2%.²²

Barriers to pediatric retention include caregiver fatigue, difficulty accessing age-appropriate drug formulations, and the fact that young children depend entirely on adults to keep appointments and administer medications. Getting pediatric viral load testing done also lags: in one chart review, fewer than 40% of children alive and in care had gotten a CD4 count in the prior six months.²²

Stigma, Criminalization, and Access to Care

HIV-related stigma remains a powerful barrier in Nigeria. Survey data has found that roughly 40% of people in the general population would not agree that a female teacher living with HIV should be allowed to keep teaching, even if she is not sick.²³ That kind of everyday discrimination shapes whether people seek testing, disclose their status, or stay in care.

For sexual and gender minorities, the legal environment compounds the problem. Nigeria’s Same Sex Marriage Prohibition Act criminalizes same-sex relationships, and qualitative research among sexual minority men living with HIV documents how religious institutions reinforce stigma through homophobic messaging, while the law itself creates an environment of fear, violence, and social exclusion.²⁴ The practical effects include delayed testing, limited disclosure to partners and providers, and difficulty sustaining treatment.²⁵ In northern Nigeria, some Islamic prophetic healers have encouraged patients to forgo antiretroviral therapy in favor of faith-based cures, creating another avenue through which people fall out of evidence-based care.²⁶

Prevention Gaps Around PrEP

Pre-exposure prophylaxis, the daily pill that prevents HIV acquisition, works exceedingly well when taken consistently. In one Nigerian program covering key populations, over 99.9% of participants who initiated PrEP remained HIV-negative, with only two seroconversions among thousands of clients, both in people who did not complete even one month of the medication.²⁷ The problem is not efficacy; it is staying on the medication. Among more than 43,000 people who started PrEP in a large-scale program, the six-month continuation rate was only about 12%. Female sex workers had the highest continuation at about 14%, while transgender individuals had the lowest at roughly 4%.²⁸

Broader uptake trends tell a similar story of partial progress. PrEP initiation expanded between 2020 and 2022 but then declined from 2023 to 2024. Uptake has been overwhelmingly concentrated among married individuals and serodiscordant couples, reflecting a delivery system that works best when PrEP is integrated into partner testing at clinics. Unmarried people, younger age groups, and sex workers are significantly underrepresented, pointing to major prevention gaps that current delivery models are not closing.²⁹

Conflict, Displacement, and HIV Risk

The Boko Haram insurgency and intercommunal violence in Nigeria’s northeast and middle belt have displaced millions of people, creating conditions that amplify HIV risk. Internally displaced persons in one study had significantly higher odds of engaging in risky sexual behavior compared with migrants, and substance use amplified that risk further.³⁰ When outreach testing was brought directly to displaced populations in the northeast, about 1.5% of the nearly 59,000 people tested were found to be HIV-positive, with prevalence higher among women than men. The majority of those identified as positive were linked to antiretroviral therapy.³¹ That kind of active outreach matters enormously in settings where health infrastructure has been damaged or destroyed and people cannot easily reach a clinic.

Supply Chain Fragility and Funding Dependence

Nigeria’s HIV treatment program runs largely on foreign money. The U.S. government, through PEPFAR, has been the single largest funder, and the current policy trajectory involves transitioning program management from international to local implementing partners, a shift that is already underway.³² Whether local organizations can sustain the same quality of care at the same scale is an open question, and it is one that comes with high stakes: any interruption in drug supply has immediate consequences for the millions of people on daily antiretrovirals.

Drug stock-outs are already a recurring problem. In a survey of health facilities in Nigeria’s Federal Capital Territory, the vast majority of respondents had experienced stock-outs at some point, with about a quarter reporting one in the past six months and a quarter admitting to regimen changes during shortages. Staff cited poor logistics and supply-chain management as the primary causes. Coping strategies, like shortening refill periods to stretch existing supplies, are stop-gaps that risk undermining adherence and fueling drug resistance. Broader analyses of the supply chain have echoed these problems and called for greater domestic funding, reduced bureaucratic bottlenecks, and exploration of local manufacturing of HIV commodities.³³

Viral Diversity in the Nigerian Epidemic

The strains of HIV circulating in Nigeria are unusually diverse compared to what you would find in many other heavily affected countries. An analysis of patients eligible for treatment in Abuja found that subtype G was the most common strain at about 31%, followed by several recombinant forms. Recombinant viruses, which are hybrids of two or more subtypes, made up roughly 69% of all strains detected.³⁴ This matters practically because drug-resistance mutations, diagnostic test performance, and even vaccine design can all be influenced by which subtypes are circulating. Most antiretroviral drugs work across subtypes, but resistance surveillance needs to account for the specific genetic backgrounds of local viruses to stay ahead of emerging problems. Nigeria’s viral diversity also reflects a long and complex epidemic shaped by population movement, urbanization, and varied transmission networks across an enormous and heterogeneous country.